The stockmarket’s Santa rally has been cancelled

An empty Piccadilly Circus — The UK market is still in the bargain basement

(Image credit: © Alamy)

“’Twas the nightmare before Christmas,” says Stephen Innes of Axi. The appearance of a new and potentially more transmissible strain of Covid-19 in southern England has squashed hopes of a traditional pre-Christmas “Santa rally”. With chaos spreading through supply chains and talk of domestic virus restrictions remaining in place until Easter, markets have not been feeling festive. The FTSE 100 fell by 2.9% on Monday before paring losses, with the FTSE 250 finishing the day down more than 2%. The price of oil dropped 4% and the pound had its worst day since September.

Recovery delayed, not denied

If the early reports about the new virus strain are accurate then “extended and severe lockdowns for the majority” of the first quarter of 2021 now look a real possibility, says Innes. That is undermining optimism about a swift economic rebound in the new year.

The UK is heading for a double-dip recession, says Dan Hanson of Bloomberg Economics. GDP was already set to contract this quarter because of the lockdown and now looks set to fall during the first three months of 2021 too. There was better news this week from America, where congressional leaders agreed on a $900bn pandemic relief package.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

For the global economy, the key story for next year remains a recovery on the back of mass vaccination, says Jeremy Warner in The Daily Telegraph. Ongoing fiscal and monetary support are laying the groundwork for a roaring 2021. Between April and June nearly “one in every three pounds earned” in the UK was being saved, with Britons now sitting on an estimated £200bn savings pile. When the pandemic is over “collectively we will want to treat ourselves”.

Buy Britain

The FTSE 100 has continued to underperform peers this year, falling 15.5% so far in 2020. That compared with a 9% fall on the Euro Stoxx 50 and a 13% rise of the S&P 500. Yet a long period of disappointment gives the FTSE room to rise, says Chris St John of AXA Investment Managers. “Deal or no-deal, we expect the FTSE 100 to go up”. A Brexit deal would give investors the confidence they need to buy into Britain again. On the other hand, no-deal would knock sterling lower, which will make FTSE 100 earnings – 70% of which come from overseas – appear stronger in pound terms. That said, the effect of a disruptive no-deal on mid- and small-cap shares would be “indiscriminately” negative.

Still, as MoneyWeek has pointed out for much of the year, near-term disruption looks to be in the price. On a cyclically adjusted price/earnings ratio (Cape) of 11.8 as of the end of October, the UK market trades at a huge discount to the developed market average of 23.4.

But tread carefully in America. The S&P 500’s Cape ratio reached 33.1 last month – higher than the 32.6 it hit in the run-up to the Wall Street crash of 1929. There is a lot of potential downside for US equities.

Explore More

Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.

Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.

He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.

Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.